Trial reportEuropean journal of clinical pharmacology2009
Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
Trial report in European journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 58 citations in OpenAlex.
- The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.Drug metabolism and disposition: the biological fate of chemicals · 2014Trial
- A Digital Twin of the Angiotensin II Receptor Blocker Losartan: Physiologically Based Modeling of Blood Pressure Regulation.Pharmaceutics · 2026Article
- Dietary supplements in integrative oncology.Frontiers in oncology · 2026Review
- Mechanistic Insights into the Pharmacological Significance of Silymarin.Molecules (Basel, Switzerland) · 2022Review
- Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.Frontiers in pharmacology · 2022Review
- Influence ofJournal of personalized medicine · 2021Review
- Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance.Life (Basel, Switzerland) · 2020Review
- Metabolism, Transport and Drug-Drug Interactions of Silymarin.Molecules (Basel, Switzerland) · 2019Review
- Herbal Interaction With Chemotherapeutic Drugs-A Focus on Clinically Significant Findings.Frontiers in oncology · 2019Review
- Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products.Cardiovascular therapeutics · 2019Review
- A regulatory science viewpoint on botanical-drug interactions.Journal of food and drug analysis · 2018Review
- Adverse Effects of Nutraceuticals and Dietary Supplements.Annual review of pharmacology and toxicology · 2018Review
- Phytotherapeutics: The Emerging Role of Intestinal and Hepatocellular Transporters in Drug Interactions with Botanical Supplements.Molecules (Basel, Switzerland) · 2017Review
- Pharmacogenomics and herb-drug interactions: merge of future and tradition.Evidence-based complementary and alternative medicine : eCAM · 2015Review
- Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction.CPT: pharmacometrics & systems pharmacology · 2014Article
- Herb-drug interactions: challenges and opportunities for improved predictions.Drug metabolism and disposition: the biological fate of chemicals · 2014Article
- Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).EXCLI journal · 2014Review
- A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors.Drug metabolism and disposition: the biological fate of chemicals · 2013Article
- Drug interactions with herbal medicines.Clinical pharmacokinetics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effects of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 and its relationship with CYP2C9 genotypes.
methodsTwelve healthy adult men of known CYP2C9 genotype (six CYP2C9*1/*1 and six CYP2C9*1/*3) were recruited in a two-phase randomized crossover design study. The pharmacokinetics of losartan and E-3174 were measured before and after a 14-day treatment with 140 mg of silymarin three times daily.
resultsThe area under the plasma concentration-time curve (AUC) of losartan increased significantly following a 14-day silymarin treatment in subjects with the CYP2C9*1/*1 genotype, but not in those with the CYP2C9*1/*3 genotype. The AUC of E-3174 decreased significantly with a silymarin pretreatment in both CYP2C9*1/*1 and the CYP2C9*1/*3 subjects. The metabolic ratio of losartan (ratio of AUC(0-infinity) of E-3174 to AUC(0-infinity) of losartan) decreased significantly after a 14-day treatment with silymarin in individuals with the CYP2C9*1/*1 genotype (p < 0.05), but not in those with the CYP2C9*1/*3 genotype (p = 0.065).
conclusionSilymarin inhibits the metabolism of losartan to E-3174, with the magnitude of the interaction differing in individuals with different CYP2C9 genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.